PD-1

[Proceedings of the National Academy of Sciences of the United States of America] Researchers examined the immune cell profile of eight cell suspension samples of Lymphocyte-rich classic Hodgkin lymphoma (LR-CHL) in comparison to 20 samples of the mixed cellularity and nodular sclerosis subtypes of CHL.

[Surface Oncology] Surface Oncology, an immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced details about its plan to initiate a randomized Phase II clinical study evaluating SRF388, in combination with Roche’s atezolizumab and bevacizumab, in patients with treatment-naïve hepatocellular carcinoma.

[International Journal of Clinical Oncology] 94 lung adenocarcinoma cases were reviewed in the Third Affiliated Hospital of Soochow University from January to December 2019. PD-L1 (DAKO 22C3) was used to test the PD-L1 expression in lung cancer tissue.

[Oncogene] Researchers found that inducing the degradation of bromodomain and extra-terminal domain (BET) proteins by the proteolysis targeting chimeras approach potently suppressed the growth of colorectal cancer including patient-derived tumors.

[Nature Communications] Researchers reported that lung epithelial cells, including distinct surfactant protein C (SPC)lowMHChigh epithelial cells, functioned as anatomically-segregated and temporally-dynamic antigen presenting cells.

[Scientific Reports] Scientists evaluated the effectiveness and safety of sintilimab, a programmed cell death protein-1 blockade, combined with sorafenib and transhepatic arterial chemotherapy and embolization in patients with unresectable hepatocellular carcinoma, compared with sintilimab monotherapy and sintilimab-sorafenib duotherapy.